

Access and Support for Your Patients Prescribed LIFYORLI

An overview of how to order LIFYORLI, as well as access and financial assistance resources

INDICATIONS & USAGE

LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens, at least one of which included bevacizumab.

IMPORTANT SAFETY INFORMATION

Contraindications: LIFYORLI is contraindicated in patients receiving systemic glucocorticoids for lifesaving purposes (e.g., immunosuppression after organ transplantation) because LIFYORLI antagonizes the effect of glucocorticoids.

Warnings and Precautions:

Neutropenia and Severe Infections: LIFYORLI in combination with nab-paclitaxel can cause neutropenia, including febrile neutropenia and severe infections. There was one fatal event of septic shock with febrile neutropenia. Monitor complete blood counts prior to each weekly treatment with LIFYORLI in combination with nab-paclitaxel and as clinically indicated. Withhold dose, reduce dose, or permanently discontinue LIFYORLI based on severity.

Adrenal Insufficiency: LIFYORLI can cause adrenal insufficiency. Adrenal insufficiency can occur at any time during treatment with LIFYORLI. Monitor for signs and symptoms of adrenal insufficiency. Withhold LIFYORLI and administer glucocorticoid therapy if adrenal insufficiency is suspected. After resolution of adrenal insufficiency, resume previous dose, reduce dose, or permanently discontinue LIFYORLI based on severity.

Exacerbation of Conditions Treated with Glucocorticoids:

Use of LIFYORLI in patients taking systemic glucocorticoids for other conditions (e.g., autoimmune disorders) may exacerbate these conditions. LIFYORLI may make systemic glucocorticoids less effective and coadministration of systemic glucocorticoids may make LIFYORLI less effective. Monitor patients for reduced effectiveness of LIFYORLI and glucocorticoids in patients receiving both.

Embryo-Fetal Toxicity: LIFYORLI can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the risk to a fetus and to use effective contraception.

Adverse Reactions:

Serious adverse reactions ($\geq 2\%$) in patients who received LIFYORLI plus nab-paclitaxel were neutropenia, pneumonia, pleural effusion, febrile neutropenia, and fatigue. Fatal adverse reactions (2.1%) were septic shock, cardiac arrest, ischemic stroke, and intestinal perforation.

The adverse reaction ($>2\%$) that resulted in permanent discontinuation of LIFYORLI in patients was intestinal obstruction. Adverse reactions ($\geq 5\%$) that required dosage interruptions of LIFYORLI in combination with nab-paclitaxel in patients included neutropenia, anemia, and fatigue. Adverse reactions requiring dose reductions of LIFYORLI included fatigue, decreased appetite, abdominal pain, neutropenia, edema, and sciatica.

The most common adverse reactions ($>20\%$) in patients who received LIFYORLI plus nab-paclitaxel, including laboratory abnormalities, were decreased hemoglobin, decreased neutrophils, fatigue, nausea, diarrhea, decreased platelets, rash, and decreased appetite.

LIFYORLI Is Available in an Oncology Optimized Limited Distribution Model

 The Oncology Optimized Limited Distribution model promotes patient-centric, in-practice care



You can prescribe and order LIFYORLI just as you would other standard oral oncolytics, using the standard pharmacy workflow.

To access nab-paclitaxel, continue to obtain the infusion medication from your current, preferred distributor.

LIFYORLI Free Trial Offer Voucher

The LIFYORLI Free Trial Offer Voucher provides one 28-day trial of LIFYORLI at no cost for eligible new patients, regardless of insurance coverage status.*

Visit LIFYORLIfreetrialvoucher.com to enroll your patients. 



*See full LIFYORLI Free Trial Offer Voucher Terms and Conditions at LIFYORLIfreetrialvoucher.com.

IMPORTANT SAFETY INFORMATION (cont'd)

Drug Interactions:

- **Strong CYP3A Inducers:** Avoid coadministration of LIFYORLI plus nab-paclitaxel with strong CYP3A inducers.
- **CYP2C8 Inducers and Moderate CYP3A Inducers:** Monitor for reduced effectiveness of LIFYORLI plus nab-paclitaxel with CYP2C8 inducers and moderate CYP3A inducers.
- **CYP2C8 Inhibitors:** Monitor for increased adverse reactions and modify the dosage for adverse reactions as recommended.
- **CYP3A Substrates:** Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP3A substrates.
- **Certain CYP2C8 Substrates:** Avoid concomitant use unless otherwise recommended in the Prescribing Information for CYP2C8 substrates.

Use in Specific Populations:

- **Lactation:** Advise women not to breastfeed during treatment with LIFYORLI and for 1 week after the last dose.
- **Geriatric Use:** A higher incidence of grade 3-4 adverse events and dosage modification occurred in patients aged ≥ 65 years compared to younger adult patients.
- **Hepatic Impairment:** Avoid LIFYORLI in combination with nab-paclitaxel in patients with moderate or severe hepatic impairment.

Please see the accompanying full [Prescribing Information](#) for additional Important Safety Information.

Support Is Available if You Need Help Getting Your Patients Started With LIFYORLI

Once a patient is enrolled in LIFYORLI Support™, a dedicated LIFYORLI Support Case Manager can help with:



Benefits investigation: Provide benefits investigation results quickly, so you can understand your patient's coverage and potential out-of-pocket costs for LIFYORLI



Prior authorization (PA) and appeals support: Identify health insurance requirements across various plan types to help your office accurately respond to PAs and take action right away in the event of a denial



Quick Start Program: Help your eligible insured patients who experience a delay in coverage get started on LIFYORLI right away at no cost for a limited time*



Reimbursement information and assistance: Answer general reimbursement questions related to nab-paclitaxel



LIFYORLI Support Case Managers can also connect your patients to LIFYORLI Support Nurse Educators to answer questions about their treatment journey with LIFYORLI†

Financial assistance is available for your patients prescribed LIFYORLI



LIFYORLI Savings Card

Eligible, commercially insured patients may pay as little as \$0 per month for LIFYORLI.‡

LIFYORLIsavingscard.com



LIFYORLI Patient Assistance Program (PAP)

Eligible patients who are uninsured or underinsured may be eligible to receive LIFYORLI at no cost.§

LIFYORLI Support will evaluate eligibility and reach out with next steps.

Dose Replacement Program for LIFYORLI



If a patient experiences a treatment interruption, contact LIFYORLI Support to learn more about the Dose Replacement Program, or visit LIFYORLIhcp.com/support to download the Dose Replacement Form.||

Lifyorli
SUPPORT™
We're here if you need us

*Please see full Quick Start Terms and Conditions at LIFYORLIenroll.com.

†A Nurse Educator cannot provide medical or clinical advice; these questions should be directed to a doctor, nurse, or pharmacist.

‡Please see Savings Card Terms and Conditions at LIFYORLIsavingscard.com.

§Please see PAP Terms and Conditions at LIFYORLIenroll.com.

||Please see Dose Replacement Program Terms and Conditions at LIFYORLIenroll.com.

Please see Important Safety Information on pages 1-2 and the accompanying full [Prescribing Information](#).

Lifyorli
(relacorilant) 100 mg, 25 mg capsules

Next steps



Download and **fax** the Enrollment Form to
1-844-854-3967

LIFYORLIhcp.com/support

OR



E-enroll your patients

LIFYORLIenroll.com

You may also enroll by calling LIFYORLI Support™ at 1-85-LIFYORLI (1-855-439-6754), Monday-Friday, 8 AM-8 PM ET, or visit LIFYORLIhcp.com/support.



Visit LIFYORLIhcp.com/support for LIFYORLI and nab-paclitaxel access resources, including:

- ✓ How to order LIFYORLI
- ✓ Billing and coding
- ✓ eRx and EHR considerations
- ✓ Coverage, denials, and appeals

EHR, electronic health record; eRx, electronic prescription.

Please see Important Safety Information on pages [1-2](#) and the accompanying full [Prescribing Information](#).



LIFYORLI, LIFYORLI Support, and the LIFYORLI logo are trademarks of Corcept. Corcept and the Corcept logo are registered trademarks. All other trademarks are the property of their respective owners. © 2026 Corcept. All rights reserved. US-REL-26-0044 03-26

